Enveric Biosciences, Inc.
$3.65
▼
-4.25%
2026-04-21 06:39:01
www.enveric.com
NCM: ENVB
Explore Enveric Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.44 M
Current Price
$3.65
52W High / Low
$17.84 / $1.71
Stock P/E
—
Book Value
$3.94
Dividend Yield
—
ROCE
-210.04%
ROE
-3.04%
Face Value
—
EPS
$-36.24
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
0.33
Debt / Equity
—
Current Ratio
5.38
Quick Ratio
5.38
Forward P/E
-1.39
Price / Sales
—
Enterprise Value
$-0.97 M
EV / EBITDA
0.11
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
| 2. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 3. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 4. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 5. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 6. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
| 7. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.19 M | -1.87 M | -2.52 M | -2.19 M | -3.17 M | — |
| Net Profit | -2.19 M | -1.87 M | -2.52 M | -2.18 M | -3.15 M | — |
| EPS in Rs | -1.16 | -0.99 | -1.33 | -1.16 | -1.67 | -43.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -8.77 M | -9.63 M | -18.3 M | -19.96 M |
| Net Profit | -8.77 M | -9.57 M | -17.31 M | -18.5 M |
| EPS in Rs | -4.65 | -5.07 | -9.17 | -9.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.1 M | 3.08 M | 4.3 M | 19.55 M |
| Total Liabilities | 0.92 M | 1.49 M | 2.34 M | 4 M |
| Equity | 4.18 M | 1.59 M | 1.96 M | 14.67 M |
| Current Assets | 4.94 M | 2.73 M | 3.58 M | 18.43 M |
| Current Liabilities | 0.92 M | 1.49 M | 2.34 M | 4 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.14 M | -7.73 M | -14.09 M | -17.15 M |
| Investing CF | — | 0 M | 0.01 M | -0.58 M |
| Financing CF | 10.58 M | 7.67 M | -1.34 M | 18.18 M |
| Free CF | -8.14 M | -7.73 M | -14.1 M | -17.73 M |
| Capex | — | — | -0.01 M | -0.58 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 44.69% | 6.45% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-10-28 | 1:0.0833333 |
| 2025-01-29 | 1:0.0666667 |
| 2025-01-27 | 1:0.0666667 |
| 2022-07-15 | 1:0.02 |